Several late-stage cancer-readouts moved the treatment conversation this week, with new efficacy signals spanning immuno-oncology and targeted therapy strategies. In advanced lung cancer, Roche and AstraZeneca highlighted differentiated approaches to drug resistance pathways, while additional conference updates focused on how biomarker-defined subgroups may respond. Across the updates, the throughline is that trial design is increasingly centered on overcoming or extending beyond resistance mechanisms—using next-generation targeted agents or checkpoint combinations. The industry will watch whether these readouts translate into durable endpoints and whether subgroup effects hold in confirmatory settings. In parallel, investors and clinicians are tracking how these programs may compete in overlapping lines of therapy and where the strongest differentiation emerges clinically—especially for previously treated populations or patients with hard-to-treat genomic subsets. Overall, the reads reinforce a shift toward precision-driven development plans and combination regimens staged to capture both survival and response depth in defined biomarker contexts.